Equities

Wuhan YZY Biopharma Co Ltd

Wuhan YZY Biopharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)7.45
  • Today's Change0.00 / 0.00%
  • Shares traded800.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 07 2024 04:41 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The Company is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The Company's drug products are mainly used in major diseases such as tumor, immunity, inflammation, cardiovascular and infection.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-206.90m
  • Incorporated2010
  • Employees123.00
  • Location
    Wuhan YZY Biopharma Co LtdNo. 666 Gaoxin RoadEast Lake High Tech Development ZoneWUHAN 430075ChinaCHN
  • Phone+86 2 782668988
  • Fax+86 2 768788819
  • Websitehttps://www.yzybio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hbm Holdings Ltd699.15m178.08m1.05bn177.005.661.074.921.510.24220.24220.95261.280.38863.903.013,950,022.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61---12.62--
Sunho Biologics Inc-100.00bn-100.00bn1.09bn-------------------------------------------------------155.25------
Ascletis Pharma Inc61.00m-155.98m1.14bn219.00--0.4668--18.76-0.1466-0.14660.05682.420.0222.303.86278,539.90-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04---20.44--
Jacobson Pharma Corporation Ltd1.68bn212.16m1.22bn1.59k5.480.51143.080.72490.11120.14090.88221.190.37222.877.50940,829.505.164.916.616.6042.0541.8113.8514.321.015.620.364635.9711.912.8941.304.42-6.226.39
VIVA Biotech Holdings2.32bn-125.15m1.34bn2.08k--0.334111.160.5768-0.0637-0.06371.201.860.28054.845.211,118,595.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.151.000.3412---9.4259.3178.03--31.98--
Jacobio Pharmaceuticals Group Co Ltd68.46m-387.07m1.39bn301.00--1.20--20.24-0.5007-0.50070.08861.460.0419--5.21227,452.00-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43--19.18--
Wuhan YZY Biopharma Co Ltd0.00-206.62m1.44bn123.00--10.50-----1.11-1.110.000.7098------0.00----------------1.41-100.120.4138-------1.50------
Essex Bio-Technology Ltd1.71bn275.26m1.45bn1.48k5.440.75234.320.8480.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
Mabpharm Ltd93.94m-225.65m1.51bn347.00--6.81--16.02-0.0547-0.05470.02280.05360.08930.11766.02270,731.30-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
CStone Pharmaceuticals499.94m-395.81m1.52bn230.00--3.08--3.03-0.3138-0.31380.39580.38340.28112.443.722,173,642.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
Immunotech Biopharm Ltd0.00-360.87m1.53bn211.00--8.19-----0.7013-0.70130.000.36370.00----0.00-38.88-37.42-50.88-45.48--------1.03-2.510.4327-------5.25---8.46--
Hua Medicine82.57m-227.67m1.54bn177.00--13.13--18.66-0.2329-0.23290.08450.11120.05381.6913.03466,506.80-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80--14.07--
Cryofocus Medtech Shanghai Co Ltd44.14m-105.07m1.65bn392.00--9.49--37.43-0.4394-0.43940.18460.7278------112,593.60--------75.83---258.23--4.08--0.0597--50.83--13.13------
TOT Biopharm International Co Ltd841.38m-40.70m1.70bn551.00--2.30323.772.02-0.0561-0.05611.160.95770.58081.878.031,526,999.00-2.81-20.01-3.72-25.2173.5374.74-4.84-68.531.48-4.600.3348--76.5481.8824.36--21.04--
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn351.37m1.77bn1.14k5.050.57543.921.430.23380.23380.82572.050.31562.316.371,085,499.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
SinoMab Bioscience Ltd1.47m-262.03m1.90bn215.00--5.65--1,291.21-0.2574-0.25740.00150.30780.0015----6,842.90-26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---11.480.604------14.45--106.81--
Data as of Jun 07 2024. Currency figures normalised to Wuhan YZY Biopharma Co Ltd's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.